Pfizer (NYSE:PFE) Stock Price Down 1.4% – Here’s Why

Shares of Pfizer Inc. (NYSE:PFE) traded down 1.4% on Friday . The company traded as low as $28.38 and last traded at $28.42. Approximately 23,419,310 shares changed hands during trading, a decline of 44% from the average session volume of 41,591,715 shares. The stock had previously closed at $28.81.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched the Phase 3 VESPER-JM study of obesity candidate berobenatide in Japan. The trial strengthens Pfizer’s effort to compete in the rapidly expanding obesity-drug market and supports management’s expectation that the product could contribute to growth from 2028 onward. Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan
• Positive Sentiment: Pfizer’s Phase 3 tilrekimig eczema program provides another late-stage pipeline catalyst, while the completed Phase 1 migraine-tablet study demonstrates continued efforts to diversify beyond COVID-19 products. Pfizer’s Tilrekimig Eczema Trial
• Positive Sentiment: The FDA approved Pfizer’s 2026–2027 COMIRNATY XFG COVID-19 vaccine formula for high-risk age groups, supporting near-term vaccine sales and adding to the recent run of favorable company news. Pfizer After FDA Vaccine Approval Faces A Fair Value Reality Check
• Positive Sentiment: Pfizer licensed its early-stage CD228V antibody-drug conjugate to Medicus Pharma in a deal potentially worth more than $1 billion plus royalties. The agreement provides external validation and possible future economic upside, although the asset remains clinically unproven. Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
• Neutral Sentiment: Pfizer recently reported earnings above expectations, and shares are up substantially over the past year. Analysts now question how much of the pipeline and vaccine optimism is already reflected in the stock, limiting the impact of additional positive headlines. Pfizer Stock Looks Fully Valued As Earnings Run Ahead Of Value
• Negative Sentiment: Investor concerns remain focused on declining post-pandemic revenue, upcoming patent expirations and Pfizer’s ability to maintain its roughly 6% dividend while funding new growth initiatives. Some commentary characterizes the stock as a potential value trap despite its low valuation and high yield. Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

Analyst Ratings Changes

Several equities analysts have commented on PFE shares. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and reduced their price target for the company from $32.00 to $28.00 in a research note on Monday, July 6th. JPMorgan Chase & Co. lowered their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. Finally, Guggenheim dropped their price objective on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Stock Performance

The firm has a market capitalization of $161.98 billion, a price-to-earnings ratio of 37.40, a PEG ratio of 1.95 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock’s 50-day moving average is $25.90 and its 200-day moving average is $26.33.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 24th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s payout ratio is currently 226.32%.

Hedge Funds Weigh In On Pfizer

Several large investors have recently bought and sold shares of the company. California State Teachers Retirement System grew its holdings in shares of Pfizer by 2,320.6% during the second quarter. California State Teachers Retirement System now owns 217,981,455 shares of the biopharmaceutical company’s stock worth $5,248,993,000 after purchasing an additional 208,976,273 shares during the last quarter. Norges Bank bought a new stake in shares of Pfizer in the fourth quarter worth $1,830,986,000. Bank of America Corp DE acquired a new stake in Pfizer in the second quarter valued at $1,049,602,000. BlackRock Inc. lifted its holdings in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after buying an additional 31,412,883 shares during the period. Finally, Morgan Stanley grew its position in shares of Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.